Tedavi Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.25 Cr
- Revenue Growth %
- Profit Growth 2958.91%
- Ebitda 4014.09%
- Net Worth 1133.63%
- Total Assets 10423.10%
About Tedavi Lifesciences
Tedavi Lifesciences Private Limited (TLPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 July 2016 (Eight years and seven months 8 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.25 Cr.
Manoj Gupta and Chander Gupta serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909DL2016PTC303129
- Company No.
303129
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jul 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Tedavi Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Gupta  | Director | 18-Jul-2016 | Current |
| Chander Gupta | Director | 18-Jul-2016 | Current |
Financial Performance of Tedavi Lifesciences.
Tedavi Lifesciences Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 2958.91% increase in profit. The company's net worth Soared by an impressive increase of 1133.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tedavi Lifesciences?
In 2020, Tedavi Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Cmg Biotech Private LimitedManoj Gupta is a mutual person
Charges (Loans)
₹22.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 2.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Apr 2021 | Others | ₹2.25 Cr | Open |
How Many Employees Work at Tedavi Lifesciences?
Unlock and access historical data on people associated with Tedavi Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tedavi Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tedavi Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.